BigHat Biosciences
About
BigHat Biosciences is a protein therapeutics company that develops an antibody design platform guided by artificial intelligence.
- San Mateo,California,United States
- 11 - 50
- http://www.bighatbio.com
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $75M
- Industries
- Artificial Intelligence,Biotechnology,Medical,Therapeutics
- Founded date
- Jan 1, 2019
- Number Of Employee
- 11 - 50
- Operating Status
- Active
- Legal Name
- BigHat Biosciences, Inc.
- Also Known As
- BigHat
BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 20, 2022 | Series B | $75M | 9 |
Section 32
|
— | Detail |
| Feb 10, 2021 | Series A | $19M | 4 |
Andreessen Horowitz
|
— | Detail |
| Oct 1, 2020 | Grant | — | 1 |
National Institute of Standards and Technology
|
— | Detail |
| Dec 19, 2019 | Seed | $5.30M | 1 |
8VC
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Section 32
|
Yes | Series B |
|
National Institute of Standards and Technology
|
Yes | Grant |
Gaingels
|
— | Series B |
|
8VC
|
— | Series B |
AME Cloud Ventures
|
— | Series B |
Amgen Ventures
|
— | Series B |
|
Andreessen Horowitz
|
— | Series B |
Bristol Myers Squibb
|
— | Series B |
GRIDS Capital
|
— | Series B |
Quadrille Capital
|
— | Series B |
Employee Profiles
Acquisition
BigHat Biosciences has acquired 1 organizations. Their most recent acquisition was Frugi Biotechnology on Mar 28, 2022. They acquired Frugi Biotechnology for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Mar 28, 2022
|
Biotechnology | acquisition | — | Detail |
